ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Panel Calls For New Office, Advisory Groups To Oversee NCI’s Translational Research.

June 22, 2007

PIs On Both Sides of Screening Controversy Testified in Tobacco Trials.

October 26, 2007

NCI News: Communications Office Seeks Partners for Education Programs

October 11, 1996

In Brief: Grants Compromise Still In Doubt As Natcher, Conte Hold Out for 6,500; House Marks Up Bill

July 12, 1985

Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval

August 31, 2012

CCRAC Members Say Practicing Physicians Do Not Use Cancer Prevention Methods

August 24, 1979